What are the clinical implications of new onset or worsening anxiety during the first two weeks of SSRI treatment for depression?

Depression and Anxiety

Volumn 29, Issue 2, 2012, Pages 94-101

  Gollan, Jackie K ^a   Fava, Maurizio ^b   Kurian, Benji ^c   Wisniewski, Stephen R ^d   Rush, A John ^e   Daly, Ella ^c   Miyahara, Sachiko ^f   Trivedi, Madhukar H ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Anxiety; Change; Depression; Outcome; SSRI

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; OUTPATIENT; PREVALENCE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; DEPRESSIVE DISORDER, MAJOR; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS;

EID: 84859812520     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.20917     Document Type: Article

References (45)

1. Preskorn SH, Stanga CY, Ross R. Selective serotonin reuptake inhibitors. In: Preskorn SH, Stanga CY, Feighner JP, Ross R, eds. Antidepressants: Past, Present, and Future, Vol 157. Berlin, New York: Springer; 2004:241-262.
2. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analyses of efficacy and tolerability. J Affect Disord 2000;58:19-36. (Pubitemid 30173208)
3. Papakostas GI, Trivedi MH, Alpert JE, et al. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: a meta-analysis of individual patient data from 10 double-blind, randomized clinical trials. J Psychiatr Res 2008;42:134-140. (Pubitemid 350061259)
4. Rush AJ, Trivedi MH, Ibrahim HM, et al. Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline. Neuropsychopharmacology 2001;24:131-138. (Pubitemid 32493829)
5. Trivedi MH, Rush AJ, Carmody TJ, et al. Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients? J Clin Psychiatry 2001;62:776-781. (Pubitemid 33104664)
6. Beasley Jr CM, Dornseif BE, Pultz JA, Bosomworth JC, Sayler ME. Fluoxetine vs. trazodone: efficacy and activating-sedating effects. J Clin Psychiatry 1991;52:294-299.
7. Kessler RC, Nelson CB, McGonagle KA, Liu J, Swartz M, Blazer DG. Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey. Br J Psychiatry Suppl 1996;30:S17-S30.
8. Fava M, Alpert JE, Carmin C, et al. Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. Psychol Med 2004;34:1299-1308. (Pubitemid 39517160)
9. Fava M, Rush AJ, Alpert JE, et al. What clinical and symptom features of comorbid disorders characterize outpatients with anxious major depressive disorder: a replication and extension. Can J Psychiatry 2006;51:823-835. (Pubitemid 46354060)
10. Fava M, Rush AJ, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry 2008;165:342-351. (Pubitemid 351704490)
11. Fawcett J, Kravitz HM. Anxiety symptoms and their relationship to depressive illness. J Clin Psychiatry 1983;44:8-11. (Pubitemid 13037504)
12. Marcus SM, Kerber KB, Rush AJ, et al. Sex differences in depression symptoms in treatment-seeking adults: confirmatory analyses from the sequenced treatment alternatives to relieve depression study. Compr Psychiatry 2008;49:238-246.
13. Joffe RT, Bagby RM, Levitt A. Anxious and nonanxious depression. Am J Psychiatry 1993;150:1257-1258. (Pubitemid 23218913)
14. Jeste ND, Hays JC, Steffens DC. Clinical correlates of anxious depression among elderly patients with depression. J Affect Disord 2006;90:37-41. (Pubitemid 43005035)
15. Davidson JR, Meoni P, Haudiquet V, Cantillon M, Hackett D. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms. Depress Anxiety 2002;16:4-13. (Pubitemid 34977120)
16. Van Valkenburg C, Akiskal HS, Puzantian V, Rosenthal T. Anxious depressions: clinical, family, history, and naturalistic outcome: comparisons with panic and major depressive disorders. J Affect Disord 1984;6:67-82. (Pubitemid 14158974)
17. Ramana R, Paykel ES, Cooper Z, Hayhurst H, Saxty M, Surtees PG. Remission and relapse in major depression: a two-year prospective follow-up study. Psychol Med 1995;25:1161-1170.
18. Zimmerman M, Mattia JI. The psychiatric diagnostic screening questionnaire: development, reliability and validity. Compr Psychiatry 2001a;42:175-189. (Pubitemid 32410920)
19. Zimmerman M, Mattia JI. A self-report scale to help make psychiatric diagnoses: the psychiatric diagnostic screening questionnaire. Arch Gen Psychiatry 2001b;58:787-794. (Pubitemid 32717805)
20. Rush AJ, Carmody TJ, Reimitz PE. The inventory of depressive symptomatology (IDS): clinician (IDS-C) and self-report (IDS-SR) ratings of depressive symptoms. Int J Methods Psychiatr Res 2000;9:45-59.
21. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003;54:573-583. (Pubitemid 37289444)
22. Trivedi MH, Rush AJ, Ibrahim HM, et al. The inventory of depressive symptomatology, clinician rating (IDS-C) and self-report (IDS-SR), and the quick inventory of depressive symptomatology, clinician rating (QIDS-C) and self-report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med 2004;34:73-82. (Pubitemid 38139442)
23. American Psychological Association. Diagnostic and Statistical Manual of Mental Disorders - Text Revision. Washington, DC: American Psychiatric Association; 2000.
24. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28-40. (Pubitemid 43050100)
25. Trivedi MH, Daly EJ. Measurement-based care for refractory depression: a clinical decision support model for clinical research and practice. Drug Alcohol Depend 2007;88:S61-S71. (Pubitemid 46528065)
26. Trivedi MH, Rush AJ, Gaynes BN, et al. Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR*D measurement-based care. Neuropsychopharmacology 2007;32:2479-2489. (Pubitemid 350126843)
27. Levine J, Schooler NR. SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull 1986;22:343-381. (Pubitemid 16043808)
28. Wisniewski SR, Rush AJ, Balasubramani GK, Trivedi MH, Nierenberg AA. Self-rated global measure of the frequency, intensity, and burden of side effects. J Psychiatr Pract 2006;12:71-79. (Pubitemid 44284089)
29. Fava M, Rush AJ, Trivedi MH, et al. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am 2003;26: 457-494. (Pubitemid 36583573)
30. Rush AJ, Fava M, Wisniewski SR, et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 2004;25:119-142. (Pubitemid 38230109)
31. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988;56:893-897. (Pubitemid 19008360)
32. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
33. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-296.
34. Cleary P, Guy W. Factor analysis of the Hamilton depression scale. Drugs Exp Clin Res 1977;1:115-120.
35. Tollefson GD, Holman SL, Sayler ME, Potvin JH. Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features. J Clin Psychiatry 1994;55:50-59. (Pubitemid 24081821)
36. Montgomery SA. The efficacy of fluoxetine as an antidepressant in the short and long term. Int Clin Psychopharmacol 1989;4:113-119.
37. Rush AJ, Zimmerman M, Wisniewski SR, et al. Comorbid psychiatric disorders in depressed outpatients: demographic and clinical features. J Affect Disord 2005;87:43-55. (Pubitemid 40828202)
38. Fava M, Rosenbaum JF, Hoog SL, Tepner RG, Kopp J, Nilsson ME. Fluoxetine vs sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression. J Affect Disord 2000;59:119-126. (Pubitemid 30317428)
39. Harvey AT, Preskorn SH. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part II. J Clin Psychopharmacol 1996;16:345-355. (Pubitemid 26352663)
40. Ereshefsky L, Riesenmann C, Lam YW. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6. Clin Pharmacokinet 1995;29:10-19.
41. Ressler KJ, Mayberg HS. Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic. Nat Neurosci 2007;10:1116-1124. (Pubitemid 47339944)
42. Flint AJ, Rifat SL. Two-year outcome of elderly patients with anxious depression. Psychiatry Res 1997;66:22-31.
43. Roose S, Glassman, Walsh B, Woodrin S. Tricyclic responders: phenomenology and treatment. Am J Psychiatry 1986;143:345-348. (Pubitemid 16034095)
44. Warden D, Trivedi MH, Wisniewski SR, et al. Early adverse events and attrition in SSRI treatment: a suicide assessment methodology study (SAMS) report. J Clin Psychopharmacol 2010;30:259-266.
45. Demyttenaere K, Enzlin P, Dewe W, et al. Compliance with antidepressants in a primary care setting, 1: beyond lack of efficacy and adverse events. J Clin Psychiatry 2001;62: S30-S33.